Aragon Surgical: Start-Up Diversifies Early
This article was originally published in Start Up
Executive Summary
One of the golden rules of medical device start-ups is maintaining focus. That's why it was somewhat surprising to see that Aragon Surgical Inc., a start-up just emerging from stealth status, launched by veteran device investors Leslie Bottorff of Onset Ventures and David Douglass and John Maroney of Delphi Ventures, had recently completed an acquisition of a second product while its primary product still remains very much in the development stage.
You may also be interested in...
Start-Up Quarterly Statistics, Q1 2008
Start-Up analyzes fundraising and alliances among start-ups in the biopharmaceutical, medical device and in vitro diagnostics segments from January through March 2008. Data comes from Windhover’s Strategic Transactions Database.
Novasys: Using Clinical Trials to Drive Adoption for Incontinence
Novasys Medical is using radio frequency (RF) energy to treat stress urinary incontinence in women. The company chose to adopt a much more rigorous and expensive clinical trials strategy than was needed to gain FDA approval of its device. This approach flummoxed the FDA,, slowing approval of the company's IRenessaI system. Novasys is betting that the enhanced data collected from its clinical study will result in the company gaining faster reimbursement that it hopes will drive adoption.
Falling At The Start Line: Chinese Firms Face Multiple Commercial Challenges Beyond Price, Coverage
Sales of a global first-in-class dermatology drug that gained its first approval in China are falling well behind those of its overseas counterpart. In this case study, Scrip takes a deep dive into the multiple underlying factors determining success in the world's second-largest pharma market beyond pricing and reimbursement coverage, including complex hospital entry, dual channels and competition considerations.